Recently, a double-blinded, randomized phase 2 trial demonstrated that combining adavosertib with gemcitabine resulted in significantly longer PFS and OS compared to gemcitabine alone in platinum-refractory/resistant ovarian cancer, enriched with TP53 mutations [110]. Here, TP53 is linked to ovarian carcinoma.